Drug discovery
Work with us to identify and advance novel approaches with the potential to deliver the next generation of cancer medicines.
Inivata completes £39.8 million ($52.6M) series B round
Inivata Limited, a leader in liquid biopsy, today announced it has completed a £39.8 million ($52.6 million) series B round to advance the U.S. commercial rollout of its non-small cell lung cancer liquid biopsy following a positive coverage decision from Medicare contractor Palmetto GBA earlier this month.
- 28 March 2019
Existing investors Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital and Johnson & Johnson Innovation – JJDC all participated in the round, alongside new investor RT Ventures.
Inivata’s proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute and the University of Cambridge.
Learn more here: https://www.inivata.com/inivata-completes-52-6m-39-8m-series-b-funding-round/
Related content
Drug discovery and development
We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.